Tech Company Financing Transactions
Vico Therapeutics Funding Round
Ackermans & Van Haaren, Droia Ventures and EQT Life Sciences participated in a $70.7 million Series B funding round for Vico Therapeutics. The funding round was announced by the company on 6/24/2024.
Transaction Overview
Company Name
Announced On
6/24/2024
Transaction Type
Venture Equity
Amount
$70,700,000
Round
Series B
Investors
Kurma Partners (Daniel Parera)
Seroba Life Sciences (Catello Somma)
Proceeds Purpose
The growth capital will help the Company to bolster its clinical programs to deliver life-changing outcomes for patients with polyQ diseases, such as SCA and Huntington's.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
BioScience Park BioPartner Building 1 J.H. Oortweg 21
Leiden, 2333 CH
The Netherlands
Leiden, 2333 CH
The Netherlands
Phone
Website
Email Address
Overview
Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Our lead product candidate, VO659, is currently in Phase 1/2a clinical development for the treatment of spinocerebellar ataxia types 3 and 1 and Huntington's disease and is the only ASO in the clinic that targets the underlying CAG repeat expansions that cause all nine known polyglutamine diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Micah Mackison
Chief Medical Officer
Scott Schobel
Chief Scientific Officer
Nicole Datson
Browse more venture capital transactions:
Prev: 6/24/2024: Connect Money venture capital transaction
Next: 6/24/2024: Tandem Health venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs